Pacifico Biolabs Raises €7M to Turn Germany’s Idle Breweries into Alternative Protein Factories

Europe's beer consumption has been in long-term decline, leaving significant fermentation capacity idle. Pacifico's process is designed to run inside existing brewery tanks without major modifications, leveraging the specific tank geometry, control systems, and cleaning protocols those facilities already maintain . This asset-light approach dramatically cuts two critical barriers for alternative protein startups:

• Capital expenditure: Avoiding new-build fermentation facilities removes tens of millions in upfront costs .
• Speed to production: Retrofitting takes far less time than constructing a greenfield plant .

The company claims this model puts it on a path to price parity with conventional meat—a milestone that has remained elusive for many precision-fermentation competitors .

Series A Investors

The round was led by Stray Dog Capital. Other participants included:

• Technologiegründerfonds Sachsen (TGFS)
• Sprout & About Ventures
• Simon Capital
• FoodLabs
• An undisclosed regional brewery partner

This follows earlier raises: a $3.3 million pre-seed round in early 2024 (co-led by Simon Capital and FoodLabs) and €680,000 in public funding secured in 2025 .

Why It Matters: Domestic Protein and Supply-Chain Resilience

Europe imports roughly 70% of its protein for animal feed—primarily soy from South America—creating both a large carbon footprint and a strategic vulnerability . Pacifico Biolabs frames its mycelium protein as a domestically produced alternative that reduces that import dependence.

By tapping underutilized industrial infrastructure, the company also sidesteps the land-use and agricultural constraints that limit plant-based protein scalability in Europe .

Scaling Plans and Product Roadmap

The Series A funds are directed toward three main areas:

• Production scale-up in Saxony, Germany, targeting an output of 200 tonnes per month.
• Team expansion across fermentation science, engineering, and commercial roles .
• Commercial launches in the DACH region (Germany, Austria, Switzerland) and Nordic Europe, with products expected to reach retail shelves via brand and retailer partners by late 2026 .

The company is initially focused on whole-cut meat alternatives—primarily beef and poultry formats—though earlier development work also explored seafood analogues using the same mycelium platform .

Pacifico Biolabs' brewery-retrofit strategy may offer a blueprint for other fermentation startups facing the same capital-intensity problem. Whether the model proves economically viable at scale will depend on execution in Saxony and the consumer reception when products hit shelves later this year.